Abstract: A system for performing ophthalmic surgery includes a robotic positioning system including an end effector. The robotic positioning system is configured to position the end effector with at least five degrees of freedom. An ophthalmic surgical instrument is mounted to the end effector along with an accessory device configured to facilitate performance of an ophthalmic treatment by the ophthalmic surgical instrument. The robotic positioning system may be controlled to enforce anatomical boundaries and implement predefined motion profiles.

Abstract: A system includes an actuator, one or more items of diagnostic equipment configured to perform ophthalmic measurement, and one or more items of treatment equipment configured to facilitate performance of an ophthalmic treatment with respect to an eye of a patient. A controller is coupled to the actuator and is configured to cause the actuator to transfer the one or more items of diagnostic equipment and the one or more items of treatment equipment into and out of a region in front of an eye of the patient. The ophthalmic treatment may be a LASIK or SMILE treatment using refractive error and/or eye geometry measured using the diagnostic equipment.

Abstract: A method of reducing or relieving immune inhibition in a mammal includes the step of at least partly inhibiting or reducing CD96 activity in one or more cells of the mammal to thereby relieve immune inhibition and/or enhance or restore immune surveillance in the mammal. Typically, inhibiting or reducing CD96 activity does not include, or depend upon, killing of CD96-expressing cells in the mammal. The method relieves immune inhibition and/or enhances or restores immune surveillance in the mammal to thereby treat or prevent cancer or cancer metastasis and/or a viral infection in the mammal. Also provided is a method of screening, designing, engineering or otherwise producing a CD96-inhibitory agent that relieves immune inhibition and/or enhances or restores immune surveillance in a mammal. Typically, the CD96-inhibitory agent is an antibody or antibody fragment and the mammal is a human.

Abstract: A method of determining common three-dimensional structural features of protein surfaces is provided, as is use of representations of these common structures in molecular database searching and in designing focussed molecular libraries. The method is particularly concerned with the analysis and representation of protein surfaces such as b-turns, loops and contact surfaces. In one form, the method identifies common locations and orientations of amino acid side-chains, simplified as C?-C? vectors. In another form, the method identifies common regions of surface charge represented by grid points in three-dimensional space. Further provided are common three dimensional structural features of proteins that can be used to search molecular databases for the purposes of identifying molecules that match these common three dimensional structural features.